Shannuo Li Awarded PhRMA Foundation Fellowship for Cancer Immunotherapy Research
Shannuo Li, a PhD student in Molecular Pharmaceutics, has been awarded a prestigious PhRMA Foundation Fellowship by the PhRMA Foundation Board in recognition of her outstanding research in cancer immunotherapy.
Li’s research focuses on developing next-generation immune-engaging platforms, including the Multi-Antigen T Cell Hybridizer (MATCH), to improve the safety and effectiveness of immunotherapies for multiple myeloma and other hard-to-treat cancers. Her work aims to create more flexible and precise treatments that can overcome tumor heterogeneity and treatment resistance while reducing harmful side effects.
“I was incredibly grateful and excited to receive the fellowship,” Li said. “It was very encouraging to see my work recognized, and it gave me renewed motivation to continue pushing the research forward.”
As she enters the later stages of her PhD training, Li is focused on advancing her research toward translational and preclinical studies, as well as preparing manuscripts and conference presentations. She is especially excited to see her work move closer to potential clinical application.
Li expressed her appreciation for the support of her mentors, Dr. Jindřich Kopeček and Dr. Jiyuan Yang, and noted that the fellowship provides critical support that allows her to focus on high-impact research while gaining valuable professional development experience.
Congratulations to Shannuo Li on this outstanding achievement and well-deserved recognition!
